Retrospective multicenter analysis shows favorable outcomes of IL-17 and IL-23 inhibitors in erythrodermic psoriasis, indicating a need for standardized guidelines.
There is a wide variety of treatment approaches. Standardized guidelines are needed. Biologic therapies, especially interleukin (IL)17 and IL23-inhibitors, showed favorable outcomes in this cohort and warrant prospective evaluation.
No takes yet. Share an insight, caveat, or question.
Kögel et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: